Two-Tier OTC Monograph Approach Could Come With User Fee Revamp

One tier could provide two-year exclusivity, should FDA request clinical trials for new conditions or ingredients, under a US Senate discussion draft. Essentially stalled monograph process would be replaced by deadlines for FDA action in under two years.

Industry could have two tracks for seeking changes to OTC products marketed under the US monograph system: one for adding new ingredients or medical conditions treated by those ingredients, which would be eligible for exclusivity when clinical trials are required, and another for other types of changes.

The approach is proposed in a discussion draft of legislation to create a user fee program for OTC...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Legislation

Coping Strategies For China Industry Amid BIOSECURE Overhang

 
• By 

With the US BIOSECURE Act waiting for a Senate vote, there are signs it may be prompting some Chinese firms to look at their operations. In the meantime, two legal experts in China suggest a range of coping strategies for companies that may be deemed "of concern."

EU Pharma Reform: What You Need to Know Now

 

As the reform of the EU pharmaceutical legislation progresses through the legislative process, the Pinks Sheet offers an infographic highlighting some of the key changes being proposed that will reshape the way drug companies run their business.

PBM Legislation: Medicare Rebate Reform May Be Challenging Amid Disruption From Redesign

 
• By 

US lawmakers will undoubtedly continue to work on pharmacy benefit manager reform legislation in 2025, given its bipartisan support. But policies impacting rebates that could lead to higher premiums in Part D may be a tough sell in the midst of the benefit redesign.

US Presidential Elections: Are Prescription Drug Pricing Reforms Losing Political Luster?

 
• By 

Neither Kamala Harris nor Donald Trump mentioned drug pricing reforms in their presidential convention speeches.

More from Pink Sheet

Test FDA Voucher Program Approvals Will Come From Product Centers, But Ambiguity Lingers

 
• By 

It is unclear in a revised staff manual guide whether Commissioner's National Priority Voucher program approval “recommendations” from the drug and biologic center directors will be advisory or decisional, experts told the Pink Sheet.

COVID Vaccines: US FDA Changes Course, Wants New Formulas To Target KP.2 Subvariant ‘If Feasible’

 
• By 

Revised recommendation is based on most recent data on circulating strains in US, where KP.3 is now dominant. Novavax sticks with plans targeting the JN.1 ‘parent strain.’

Nancy Tests New Podcast Template

 

Pink Sheet reporter and editors discuss the US FDA’s changes to the COVID-19 vaccine indication and its revocation of the vaccine emergency use authorizations, as well as new vaccine coverage and reimbursement questions.